PolyPid Gains After FDA Accepts D-PLEX100 NDA, Grants Priority Review
PolyPid Ltd. shares climbed after the U.S. Food and Drug Administration accepted the company’s New Drug Application for D-PLEX100 and assigned priority review for use in preventing surgical site infections in abdominal colorectal surgery. The agency set a PDUFA target action date of November 28, 2026, moved up about one quarter from the company's p…